CN105055324A - Platinum anticancer oxaliplatin composition - Google Patents
Platinum anticancer oxaliplatin composition Download PDFInfo
- Publication number
- CN105055324A CN105055324A CN201510608711.1A CN201510608711A CN105055324A CN 105055324 A CN105055324 A CN 105055324A CN 201510608711 A CN201510608711 A CN 201510608711A CN 105055324 A CN105055324 A CN 105055324A
- Authority
- CN
- China
- Prior art keywords
- oxaliplatin
- weight portion
- crystal
- platinum
- dihydrogen phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The invention discloses a platinum anticancer oxaliplatin composition, belonging to the technical field of medicines. The composition comprises oxaliplatin and sodium dihydrogen phosphate, wherein oxaliplatin is a crystal. An X-ray powder diffraction pattern obtained through measurement by using a Cu-Kalpha ray is shown in a drawing 1 in the specification. A new crystal form of oxaliplatin provided by the invention is different from the crystal structure of the prior art. Through experimental verification, the compound in the new crystal form has high purity, good flowability and stability and low impurity content, has low possibility of moisture absorption and is safe and reliable to apply clinically. Powder injections prepared by utilizing the compound in the new crystal form have good stability after undergoing compatibility with solvents, have low content of insoluble particles and are very suitable to apply clinically.
Description
Technical field
The invention belongs to medical art, relate to a kind of platinum-containing anticancer drug oxaliplatin combination thing.
Background technology
Oxaliplatin is the third generation platinum-containing anticancer drug after cisplatin, carboplatin, all has broad-spectrum anti-tumor activity in vivo and in vitro, also has cytotoxicity to the tumor cell of resistance to cisplatin.In vivo with in vitro study, all can be observed the synergistic cytotoxicity of oxaliplatin and 5-fluorouracil use in conjunction.Oxaliplatin untoward reaction is few, there is not the Toxicity of Kidney of cisplatin, the bone marrow depression of carboplatin is not had yet, its Main Function position is DNA, by forming conjugate with DNA, stop it to copy and transcribe, reach the object of killing tumor cell, and anti-tumor activity spectrum, to colorectal cancer, nonsmall-cell lung cancer, gastric cancer, ovarian cancer to various kinds of cell tumor, especially there is significant inhibitory action to the tumor cell of resistance to carboplatin, cisplatin, be used for the treatment of the patient of the transfer of the colon cancer after fluorouracil Endodontic failure, can use by fluorouracil alone or in combination.
At present, oxaliplatin as the first-line treatment medicinal application of metastatic colorectal carcinoma in clinical.When being used as treatment, oxaliplatin is with intravenous form administration.Intravenous injection is that one absorbs without human gastrointestinal tract, directly by the administering mode of infusion of medicine blood of human body, if contain from the impurity produced in raw material or production process in the preparation of injection, these impurity directly will enter blood circulation of human body without gastrointestinal tract barrier, and these impurity, even quantity is extremely small also may cause great infringement to human body.Because compound chemical change can occur in storage process as oxidation, decompose, impurity will be accumulated along with the prolongation of medicine storage time, determines that the principal element of Oxaliplatin for Injection effect duration is also the growth of total impurities in storage process.
The stability of oxaliplatin in water is all poor, and its aqueous solution can be degraded and be produced oxalic acid, two water DACH platinum, two water DACH platinum dimers and platinum class impurity.Its mesoxalic acid has toxicity because of itself, is one of impurity clearly controlled in European Pharmacopoeia oxaliplatin crude drug standard, within 2010, also has control in the first enlarged edition standard regulation to oxalic acid: must not cross 0.20% of oxaliplatin labelled amount at Chinese Pharmacopoeia.Therefore, in finished product, the minute differences of moisture also can produce significant impact to effect duration of product, the residual moisture in finished product be chemical change provide reaction medium.
In the quality standard of existing product, total impurities is an important index, therefore, strict requirement is had to total impurities in drug quality, the national drug standards (the WS1-(X-090)-2003Z of such as State Food and Drug Administration) in related substance is limited to " summation of each impurity peak area must not be greater than 1.0% of the peak area at reference substance solution main constituent peak ".(standard No.: JX20020117) regulation " total amount of impurity must not cross 1.0% of oxaliplatin labelled amount " in import drugs registered standard.
Meanwhile, oxaliplatin wettability power is comparatively strong, and especially after preparing injectable powder, wettability power grow, mobility is deteriorated, and the easy moisture absorption goes bad and occurs content uniformity.If the amount of oxaliplatin impurity, moisture therefore can be controlled well, will effectively improve the quality of product, reduce the generation of side effect, make medication safer; Also will improve the stability of medicine simultaneously, extend the effect duration of product, thus reduce selling cost.
The present inventor starts with from the research of oxaliplatin solid chemical material existence, through a large amount of experimental studies, obtain a kind of oxaliplatin crystalline compounds being different from prior art, pass through verification experimental verification, find that this crystal compound purity is high, good fluidity, good stability, impurity content is low, not easily moisture absorption, clinical practice is safe and reliable, utilize the injectable powder that this crystal compound is obtained, good stability, good with solvent compatibility rear stability, particulate matter content is extremely low, is very suitable for clinical practice.
In prior art, for the crystal formation of oxaliplatin, had many research, but the hygroscopicity of impurity content, stability and crystal formation is still undesirable, brings difficulty also to while have impact on self stability the preparation of preparation.
The present invention is through a large amount of experimental studies, and obtained a kind of oxaliplatin crystalline compounds being different from prior art, verification experimental verification finds that this crystal compound purity is high, good fluidity, good stability, impurity content is low, not easily moisture absorption, clinical practice is safe and reliable, utilize the injectable powder that this crystal compound is obtained, good stability, good with solvent compatibility rear stability, particulate matter content is extremely low, is very suitable for clinical practice.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of platinum-containing anticancer drug oxaliplatin combination thing.
In order to complete object of the present invention, the technical scheme of employing is:
A kind of platinum-containing anticancer drug oxaliplatin combination thing, consisting of of described compositions: oxaliplatin 1 weight portion, sodium dihydrogen phosphate 0.03-0.07 weight portion; Described oxaliplatin is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
Preferably, consisting of of described oxaliplatin combination thing: oxaliplatin 1 weight portion, sodium dihydrogen phosphate 0.04-0.06 weight portion.
Preferably, consisting of of described oxaliplatin combination thing: oxaliplatin 1 weight portion, sodium dihydrogen phosphate 0.05 weight portion.
Preferably, the dosage form of described oxaliplatin combination thing is injection, and the preparation method of described injection comprises the following steps:
(1) take oxaliplatin crystal and sodium dihydrogen phosphate in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
The preparation method of the oxaliplatin crystal in the present composition comprises the following steps:
Get oxaliplatin crude drug, the volume adding 30 DEG C is that in the mixed solvent A of the DMF of oxaliplatin weight 8 times, N-methylacetamide, DMF, N-methylacetamide volume ratio are 4:1, obtain solution; Then in the horizontal direction of the liquid level of gained solution, apply the stationary magnetic field that magnetic field intensity is 1.0T, and under the condition of this stationary magnetic field, in solution, drip the chloroform that volume is oxaliplatin weight 8 times; After being added dropwise to complete, be cooled to-10 DEG C, leave standstill 2 hours, filter, washing, vacuum drying, obtains described oxaliplatin crystal.
The polymorphism of solid chemical is the natural phenomena that a kind of general material exists, this phenomenon refers to that a kind of solid chemical can exist 2 kinds or two or more crystal form state, be also called the polymorphic state of material, the polymorphic state of material is also referred to as " allomorphism " phenomenon.Although its chemical nature of allomorphous solid matter is identical, its physicochemical property may be different.For " allomorphism medicine " that physicochemical property is different, also can show the curative effect of different disease preventing and treating clinically, directly affect application and the clinical effectiveness of medicine.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction that the oxaliplatin crystal of the embodiment of the present invention 1 preparation uses the measurement of Cu-K alpha ray to obtain.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1:the preparation of oxaliplatin crystal
Get oxaliplatin crude drug, the volume adding 30 DEG C is that in the mixed solvent A of the DMF of oxaliplatin weight 8 times, N-methylacetamide, DMF, N-methylacetamide volume ratio are 4:1, obtain solution; Then in the horizontal direction of the liquid level of gained solution, apply the stationary magnetic field that magnetic field intensity is 1.0T, and under the condition of this stationary magnetic field, in solution, drip the chloroform that volume is oxaliplatin weight 8 times; After being added dropwise to complete, be cooled to-10 DEG C, leave standstill 2 hours, filter, washing, vacuum drying, obtains described oxaliplatin crystal.
As shown in Figure 1, its purity of high-performance liquid chromatogram determination is 99.9% to the X-ray powder diffraction pattern that the oxaliplatin crystal prepared uses the measurement of Cu-K alpha ray to obtain.
embodiment 2:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, sodium dihydrogen phosphate 0.03 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and sodium dihydrogen phosphate in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 3:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, sodium dihydrogen phosphate 0.04 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and sodium dihydrogen phosphate in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 4:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, sodium dihydrogen phosphate 0.05 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and sodium dihydrogen phosphate in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 5:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, sodium dihydrogen phosphate 0.06 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and sodium dihydrogen phosphate in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 6:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, sodium dihydrogen phosphate 0.07 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and sodium dihydrogen phosphate in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
test example 1:draw moist test
It is moist that this test example has investigated drawing of oxaliplatin compound crystal provided by the invention, and this experiment is drawn moist test direction principle according to Chinese Pharmacopoeia 2010 editions second annex XIXJ medicine and carried out, and the results are shown in Table 1.
Table 1 draws moist result of the test
Wherein, sample 1-3 is 3 batches of products that embodiment 1 obtains
Sample 4 is the Oxaliplatin crystal compound prepared with reference to patent CN102643308B embodiment 1;
Sample 5 is the Oxaliplatin crystal compound prepared with reference to patent CN100372858C embodiment;
Sample 6 is commercially available oxaliplatin crude drug, originates from Jiangsu Aosaikang Pharmaceutical Co., Ltd..
As seen from Table 1, compared with the Oxaliplatin crystal compound of prior art, oxaliplatin hydrate crystal of the present invention to draw wet percentage weight increase little, hygroscopicity is little.
test example 2:fluidity test
This experimental example has investigated the mobility of oxaliplatin compound crystal provided by the invention.
This experimental example by working sample angle of repose assess sample mobility, concrete grammar is as follows: sample thief granule, flow into from fixing little funnel in circular surface plate, know and obtain the highest cone, measure cone height H and radius R, calculate α angle of repose by tan α=H/R, the results are shown in Table 2, angle of repose is larger, and mobility is poorer.
Table 2 fluidity test result
Wherein, sample 1-3 is 3 batches of products that embodiment 1 obtains;
Sample 4 is the Oxaliplatin crystal compound prepared with reference to patent CN102643308B embodiment 1;
Sample 5 is the Oxaliplatin crystal compound prepared with reference to patent CN100372858C embodiment;
Sample 6 is commercially available oxaliplatin crude drug, originates from Jiangsu Aosaikang Pharmaceutical Co., Ltd..
As seen from Table 2, compared with the Oxaliplatin crystal compound of prior art, oxaliplatin compound crystal of the present invention has excellent mobility, is conducive to the accuracy improving subpackage, and is easy to mix homogeneously when mixing with other compositions.
experimental example 3:solubility detection experiment
Concrete operations: get test sample 1, add water for injection 10ml, start writing time immediately, slowly rotate (0.5-1 circle/second, 2 seconds, interval), when content dissolves completely, record dwell time, should not have visible insoluble matter; Separately get 5 test sample repetitive operations, it's 3 minutes must not past average dissolution time (n=6); The dissolution time often propping up test sample must not cross 3 times of average dissolution time.Press official method simultaneously and detect visible foreign matters and particulate matter.By embodiment 2,3,4, commercially available contrast 1,2 detects as stated above, result is as following table 3.
Table 3 solubility detection experiment result
Reach a conclusion according to upper table: product of the present invention is obviously better than commercially available prod in redissolution time, visible foreign matters and particulate matter index.
experimental example 4:long term test
Sample thief, by commercially available back, place under long term test (temperature 25 DEG C ± 2 DEG C, relative humidity 65% ± 5%) condition after 4 years, detect moisture, impurity content, result is as following table 4.
The rear three batch sample assays of table 4:4
As can be seen from Table 4, the embodiment of the present invention 2,3,4 product, after temperature 25 ± 2 DEG C, relative humidity 65 ± 5% place 4 years, impurity and moisture content index are obviously better than commercially available and prior art products, and stability is better.
Similar test is carried out to other embodiments, has obtained similar result of the test.
Above-mentioned test shows the hygroscopicity that the compound tool of novel crystal forms structure of the present invention has clear improvement and higher stability, the injectable powder prepared of this oxaliplatin crystal compound compared with prior art component is simple, good stability, and moisture, impurity content are low, solubility is good, and particulate matter number is few.
Claims (5)
1. a platinum-containing anticancer drug oxaliplatin combination thing, is characterized in that: described compositions is by oxaliplatin 1 weight portion, and sodium dihydrogen phosphate 0.03-0.07 weight portion forms; Described oxaliplatin is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. platinum-containing anticancer drug oxaliplatin combination thing according to claim 1, is characterized in that: described compositions is by oxaliplatin 1 weight portion, and sodium dihydrogen phosphate 0.04-0.06 weight portion forms.
3. platinum-containing anticancer drug oxaliplatin combination thing according to claim 2, is characterized in that: described compositions is by oxaliplatin 1 weight portion, and sodium dihydrogen phosphate 0.05 weight portion forms.
4. the platinum-containing anticancer drug oxaliplatin combination thing according to any one of claim 1-3, is characterized in that, the dosage form of described compositions is injection, and the preparation method of described injection comprises the following steps:
(1) take oxaliplatin and sodium dihydrogen phosphate in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
5. platinum-containing anticancer drug oxaliplatin combination thing according to claim 1, is characterized in that, the crystal preparation method of described oxaliplatin is:
Get oxaliplatin crude drug, the volume adding 30 DEG C is that in the mixed solvent A of the DMF of oxaliplatin weight 8 times, N-methylacetamide, DMF, N-methylacetamide volume ratio are 4:1, obtain solution; Then in the horizontal direction of the liquid level of gained solution, apply the stationary magnetic field that magnetic field intensity is 1.0T, and under the condition of this stationary magnetic field, in solution, drip the chloroform that volume is oxaliplatin weight 8 times; After being added dropwise to complete, be cooled to-10 DEG C, leave standstill 2 hours, filter, washing, vacuum drying, obtains described oxaliplatin crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510608711.1A CN105055324A (en) | 2015-09-23 | 2015-09-23 | Platinum anticancer oxaliplatin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510608711.1A CN105055324A (en) | 2015-09-23 | 2015-09-23 | Platinum anticancer oxaliplatin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105055324A true CN105055324A (en) | 2015-11-18 |
Family
ID=54485011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510608711.1A Withdrawn CN105055324A (en) | 2015-09-23 | 2015-09-23 | Platinum anticancer oxaliplatin composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105055324A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217628A (en) * | 2023-05-08 | 2023-06-06 | 华东理工常熟研究院有限公司 | Eutectic of oxaliplatin Pt (IV) complex and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949353A (en) * | 2012-10-30 | 2013-03-06 | 哈药集团生物工程有限公司 | oxaliplatin lyophilized pharmaceutical composition for injection and |
| CN104523674A (en) * | 2014-12-11 | 2015-04-22 | 杨玉廷 | Injection composition with oxaliplatin as main medicine component |
| CN105125532A (en) * | 2015-09-29 | 2015-12-09 | 青岛华之草医药科技有限公司 | Medicament oxaliplatin composition for treating cancers |
-
2015
- 2015-09-23 CN CN201510608711.1A patent/CN105055324A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949353A (en) * | 2012-10-30 | 2013-03-06 | 哈药集团生物工程有限公司 | oxaliplatin lyophilized pharmaceutical composition for injection and |
| CN104523674A (en) * | 2014-12-11 | 2015-04-22 | 杨玉廷 | Injection composition with oxaliplatin as main medicine component |
| CN105125532A (en) * | 2015-09-29 | 2015-12-09 | 青岛华之草医药科技有限公司 | Medicament oxaliplatin composition for treating cancers |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116217628A (en) * | 2023-05-08 | 2023-06-06 | 华东理工常熟研究院有限公司 | Eutectic of oxaliplatin Pt (IV) complex and preparation method thereof |
| CN116217628B (en) * | 2023-05-08 | 2023-07-14 | 华东理工常熟研究院有限公司 | Eutectic of oxaliplatin Pt (IV) complex and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101389343B (en) | Doxorubicin formulations for anti-cancer use | |
| CN108938654A (en) | A kind of injection preparation of anemoside B4 | |
| CN101623284A (en) | Medical composition of compound vitamin C injection | |
| CN105055324A (en) | Platinum anticancer oxaliplatin composition | |
| CN104523674B (en) | A kind of composition for injection using oxaliplatin as main ingredient composition | |
| CN103980279B (en) | A kind of methotrexate compound and methotrexate for injection | |
| CN101467967B (en) | Double-element solution type preparation for intravenous injection and intracerebral injection | |
| AU2013377404B2 (en) | Composition of cabazitaxel and sulfobutylether beta-cyclodextrin | |
| CN105125532A (en) | Medicament oxaliplatin composition for treating cancers | |
| JP2018501291A (en) | Sulfonamide pharmaceutical composition | |
| CN101507747B (en) | Preparation method of astragalus total-saponin sodium chloride injector | |
| CN104814949B (en) | Improve chlorogenic acid acylate and the application of chlorogenic acid bioavilability | |
| CN105250317A (en) | Antitumor drug oxaliplatin composition | |
| CN111217757B (en) | Enzalutamide compound and pharmaceutical composition preparation thereof | |
| CN105078953A (en) | Anticancer oxaliplatin composition | |
| CN103142511B (en) | High-purity and high-stability composition containing oxaliplatin and preparation method of composition | |
| CN103159710B (en) | Antiviral decalin derivate | |
| CN104829653B (en) | A kind of oxaliplatin hydrate crystal and lyophilized injectable powder thereof | |
| CN101559037B (en) | Binary solution type preparation for intravenous injection and intracerebral injection | |
| AU2016311704B2 (en) | Use of dihydroxyacetone in preparation of anti-cancer medicaments | |
| CN105055308A (en) | Platinum-based antitumor drug oxaliplatin composition liquid injection | |
| CN105055347A (en) | Oxaliplatin composition freeze-dried powder injection for treating metastatic colorectal cancers | |
| CN102757471A (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN105380951A (en) | Platinum pharmaceutic preparation as well as preparation method and application thereof | |
| CN104945443A (en) | Drug, namely oxaliplatin compound, for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151118 |
|
| WW01 | Invention patent application withdrawn after publication |